Letter: Lithium-induced tremor.

D. Jarrett,J. Serry,G. Burrows

1975-01-04

Abstract:

What problem does this paper attempt to address?

The Genetic Risk Effects of APOE Ε4 and Novel Variants on Chinese Familial and Sporadic AD.

Jianping Jia,Longfei Jia,Jie Lu,Hui Xu,Fangyu Li,Shuoqi Chen,Xiu Wang,Jianwei Yang,Wei Qin,Qiumin Qu,Lan Chu,Yan-Jiang Wang,Lu Shen,Chunkui Zhou,Honglei Li,Dantao Peng,Lan Tan,Benyan Luo,Qihao Guo,Muni Tang

DOI: https://doi.org/10.1002/alz.053544

2021-01-01

Abstract:APOE ε4 positive genotype may cause familial aggregation, and the investigation of multiple interventions targeting APOE pathological function to reduce the risk for this disease warrants attention. This is the first study to validate GWAS-based predictive models for evaluating the risk of AD onset in a large Chinese population. The clinical application of these models will be beneficial for individuals harbouring these risk variants.
APOE Genotype-specific Methylation Patterns are Linked to Alzheimer Disease Pathology and Estrogen Response

Rebecca Panitch,Nathan Sahelijo,Junming Hu,Kwangsik Nho,Rhoda Au,David A Bennett,Kathryn L Lunetta,Thor D Stein,Lindsay A Farrer,Gyungah R Jun,The Alzheimer's Disease Neuroimaging Initiative

DOI: https://doi.org/10.1101/2022.12.20.22283744

2022-12-23

MedRxiv

Abstract:The joint effects of APOE genotype and DNA methylation on Alzheimer disease (AD) risk is relatively unknown. We conducted genome-wide methylation analyses using 2,021 samples in blood (91 AD cases, 329 mild cognitive impairment, 1,391 controls) and 697 samples in brain (417 AD cases, 280 controls). We identified differentially methylated levels in AD compared to controls in an APOE genotype-specific manner at 25 cytosine-phosphate-guanine (CpG) sites in brain and 36 CpG sites in blood. Additionally, we identified seven CpG sites in the APOE region containing TOMM40, APOE, and APOC1 genes with P<5x10-8 between APOE {varepsilon}4 carriers and non-carriers in brain or blood. In brain, the most significant CpG site hypomethylated in {varepsilon}4 carriers compared to non-carriers) was from the TOMM40 in the total sample, while most of the evidence was derived from AD cases. However, the CpG site was not significantly modulating expression of these three genes in brain. Three CpG sites from the APOE were hypermethylated in APOE {varepsilon}4 carriers in brain or blood compared in {varepsilon}4 non-carriers and nominally significant with APOE expression in brain. Three CpG sites from the APOC1 were hypermethylated in blood, which one of the 3 CpG sites significantly lowered APOC1 expression in blood using all subjects or {varepsilon}4 non-carriers. Co-methylation network analysis in blood and brain detected eight methylation networks associated with AD and APOE {varepsilon}4 status. Five of the eight networks included genes containing network CpGs that were significantly enriched for estradiol perturbation, where four of the five networks were enriched for the estrogen response pathway. Our findings provide further evidence of the role of APOE genotype on methylation levels associated with AD, especially linked to estrogen response pathway.
Redefining transcriptional regulation of the APOE gene and its association with Alzheimer’s disease

Eun-Gyung Lee,Jessica Tulloch,Sunny Chen,Lesley Leong,Aleen D. Saxton,Brian Kraemer,Martin Darvas,C. Dirk Keene,Andrew Shutes-David,Kaitlin Todd,Steve Millard,Chang-En Yu

DOI: https://doi.org/10.1371/journal.pone.0227667

IF: 3.7

2020-01-24

PLoS ONE

Abstract:The apolipoprotein E gene (APOE) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD), yet the expression of APOE is not clearly understood. For example, it is unclear whether AD patients have elevated or decreased APOE expression or why the correlation levels of APOE RNA and the ApoE protein differ across studies. Likewise, APOE has a single CpG island (CGI) that overlaps with its 3'-exon, and this CGI's effect is unknown. We previously reported that the APOE CGI is highly methylated in human postmortem brain (PMB) and that this methylation is altered in AD frontal lobe. In this study, we comprehensively characterized APOE RNA transcripts and correlated levels of RNA expression with DNA methylation levels across the APOE CGI. We discovered the presence of APOE circular RNA (circRNA) and found that circRNA and full-length mRNA each constitute approximately one third of the total APOE RNA, with truncated mRNAs likely constituting some of the missing fraction. All APOE RNA species demonstrated significantly higher expression in AD frontal lobe than in control frontal lobe. Furthermore, we observed a negative correlation between the levels of total APOE RNA and DNA methylation at the APOE CGI in the frontal lobe. When stratified by disease status, this correlation was strengthened in controls but not in AD. Our findings suggest a possible modified mechanism of gene action for APOE in AD that involves not only the protein isoforms but also an epigenetically regulated transcriptional program driven by DNA methylation in the APOE CGI.

multidisciplinary sciences
Non-coding Variability at the APOE Locus Contributes to the Alzheimer’s Risk

Xiaopu Zhou,Yu Chen,Kin Y. Mok,Timothy C. Y. Kwok,Vincent C. T. Mok,Qihao Guo,Fanny C. Ip,Yuewen Chen,Nandita Mullapudi,Michael W. Weiner,Paola Giusti-Rodríguez,Patrick F. Sullivan,John Hardy,Amy K. Y. Fu,Yun Li,Nancy Y. Ip

DOI: https://doi.org/10.1038/s41467-019-10945-z

IF: 16.6

2019-01-01

Nature Communications

Abstract:Alzheimer’s disease (AD) is a leading cause of mortality in the elderly. While the coding change of APOE -ε4 is a key risk factor for late-onset AD and has been believed to be the only risk factor in the APOE locus, it does not fully explain the risk effect conferred by the locus. Here, we report the identification of AD causal variants in PVRL2 and APOC1 regions in proximity to APOE and define common risk haplotypes independent of APOE -ε4 coding change. These risk haplotypes are associated with changes of AD-related endophenotypes including cognitive performance, and altered expression of APOE and its nearby genes in the human brain and blood. High-throughput genome-wide chromosome conformation capture analysis further supports the roles of these risk haplotypes in modulating chromatin states and gene expression in the brain. Our findings provide compelling evidence for additional risk factors in the APOE locus that contribute to AD pathogenesis.
Multiomics integrative analysis identifies APOE allele-specific blood biomarkers associated to Alzheimer’s disease etiopathogenesis

Laura Madrid,Sonia Moreno-Grau,Shahzad Ahmad,Antonio González-Pérez,Itziar de Rojas,Rui Xia,Pamela V. Martino Adami,Pablo García-González,Luca Kleineidam,Qiong Yang,Vincent Damotte,Joshua C. Bis,Fuensanta Noguera-Perea,Laura Madrid,Sonia Moreno-Grau,Shahzad Ahmad,Antonio González-Pérez,Itziar de Rojas,Rui Xia,Pamela V. Martino Adami,Pablo García-González,Luca Kleineidam,Qiong Yang,Vincent Damotte,Joshua C. Bis,Fuensanta Noguera-Perea,Céline Bellenguez,Xueqiu Jian,Juan Marín-Muñoz,Benjamin Grenier-Boley,Adela Orellana,M. Arfan Ikram,Philippe Amouyel,Claudia L. Satizabal,Luis Miguel Real,Carmen Antúnez-Almagro,Anita DeStefano,Alfredo Cabrera-Socorro,Rebecca Sims,Cornelia M. Van Duijn,Eric Boerwinkle,Alfredo Ramírez,Myriam Fornage,Jean-Charles Lambert,Julie Williams,Sudha Seshadri,Janina S. Ried,Agustín Ruiz,Maria Eugenia Saez,,,,,,

DOI: https://doi.org/10.18632/aging.202950

2021-04-12

Aging

Abstract:Alzheimer's disease (AD) is the most common form of dementia, currently affecting 35 million people worldwide. Apolipoprotein E (APOE) ε4 allele is the major risk factor for sporadic, late-onset AD (LOAD), which comprises over 95% of AD cases, increasing the risk of AD 4-12 fold. Despite this, the role of APOE in AD pathogenesis is still a mystery. Aiming for a better understanding of APOE-specific effects, the ADAPTED consortium analysed and integrated publicly available data of multiple OMICS technologies from both plasma and brain stratified by APOE haplotype (APOE2, APOE3 and APOE4). Combining genome-wide association studies (GWAS) with differential mRNA and protein expression analyses and single-nuclei transcriptomics, we identified genes and pathways contributing to AD in both APOE dependent and independent fashion. Interestingly, we characterised a set of biomarkers showing plasma and brain consistent protein profiles and opposite trends in APOE2 and APOE4 AD cases that could constitute screening tools for a disease that lacks specific blood biomarkers. Beside the identification of APOE-specific signatures, our findings advocate that this novel approach, based on the concordance across OMIC layers and tissues, is an effective strategy for overcoming the limitations of often underpowered single-OMICS studies.
P4-402 Alzheimer's Disease Drug Discovery Targeted to the APP MRNA 5′ Untranslated Region, a Validated Target

JT Rogers,S Payton,NH Greig,R Jensen,G Cuny,DK Lahiri,LJ Morse,RE Tanzi,D Westaway,A Bush,S Gullans,S Sarang,XD Huang

DOI: https://doi.org/10.1016/s0197-4580(04)81959-6

IF: 5.133

2004-01-01

Neurobiology of Aging

Abstract:The APOE genotype is the most prominent genetic risk factor for the development of late-onset Alzheimer’'s disease (LOAD); however, the underlying mechanisms remain unclear. In the present study, we found that the sialylation profiles of ApoE protein in the human brain are significantly different among the three isoforms, with ApoE2 exhibiting the most abundant sialic acid modification whereas ApoE4 had the least. We further observed that the sialic acid moiety in ApoE2 significantly affected the interaction between ApoE2 and Aβ peptides. The removal of sialic acid in ApoE2 increased the ApoE2 binding affinity for the Aβ17–24 region of Aβ and promoted Aβ fibrillation. These findings provide a plausible explanation for the well-documented differential roles of ApoE isoforms in Aβ pathogenesis. Specifically, compared to the other two isotypes, the higher expression of sialic acid in ApoE2 may contribute to the less potent interaction between ApoE2 and Aβ and ultimately the slower rate of brain Aβ deposition, a mechanism thought to underlie ApoE2-mediated decreased risk for AD. Future studies are warranted to determine whether the differential sialylation in ApoE isoforms may also contribute to some of their other distinct properties, such as their divergent preferences in associations with lipids and lipoproteins, as well as their potential impact on neuroinflammation through modulation of microglial Siglec activity. Overall, our findings lead to the insight that the sialic acid structure is an important posttranslational modification (PTM) that alters ApoE protein functions with relevance for AD.
In vivo validation of late‐onset Alzheimer's disease genetic risk factors

Michael Sasner,Christoph Preuss,Ravi S. Pandey,Asli Uyar,Dylan Garceau,Kevin P. Kotredes,Harriet Williams,Adrian L. Oblak,Peter Bor‐Chian Lin,Bridget Perkins,Disha Soni,Cindy Ingraham,Audrey Lee‐Gosselin,Bruce T. Lamb,Gareth R. Howell,Gregory W. Carter

DOI: https://doi.org/10.1002/alz.13840

2024-05-02

Alzheimer s & Dementia

Abstract:INTRODUCTION Genome‐wide association studies have identified over 70 genetic loci associated with late‐onset Alzheimer's disease (LOAD), but few candidate polymorphisms have been functionally assessed for disease relevance and mechanism of action. METHODS Candidate genetic risk variants were informatically prioritized and individually engineered into a LOAD‐sensitized mouse model that carries the AD risk variants APOE ε4/ε4 and Trem2*R47H. The potential disease relevance of each model was assessed by comparing brain transcriptomes measured with the Nanostring Mouse AD Panel at 4 and 12 months of age with human study cohorts. RESULTS We created new models for 11 coding and loss‐of‐function risk variants. Transcriptomic effects from multiple genetic variants recapitulated a variety of human gene expression patterns observed in LOAD study cohorts. Specific models matched to emerging molecular LOAD subtypes. DISCUSSION These results provide an initial functionalization of 11 candidate risk variants and identify potential preclinical models for testing targeted therapeutics. Highlights A novel approach to validate genetic risk factors for late‐onset AD (LOAD) is presented. LOAD risk variants were knocked in to conserved mouse loci. Variant effects were assayed by transcriptional analysis. Risk variants in Abca7, Mthfr, Plcg2, and Sorl1 loci modeled molecular signatures of clinical disease. This approach should generate more translationally relevant animal models.

clinical neurology
Novel late-onset Alzheimer disease loci variants associate with brain gene expression

Mariet Allen,Fanggeng Zou,High Seng Chai,Curtis S Younkin,Julia Crook,V Shane Pankratz,Minerva M Carrasquillo,Christopher N Rowley,Asha A Nair,Sumit Middha,Sooraj Maharjan,Thuy Nguyen,Li Ma,Kimberly G Malphrus,Ryan Palusak,Sarah Lincoln,Gina Bisceglio,Constantin Georgescu,Debra Schultz,Fariborz Rakhshan,Christopher P Kolbert,Jin Jen,Jonathan L Haines,Richard Mayeux,Margaret A Pericak-Vance,Lindsay A Farrer,Gerard D Schellenberg,Ronald C Petersen,Neill R Graff-Radford,Dennis W Dickson,Steven G Younkin,Nilüfer Ertekin-Taner,Alzheimer's Disease Genetics Consortium (ADGC),Liana G Apostolova,Steven E Arnold,Clinton T Baldwin,Robert Barber,Michael M Barmada,Thomas Beach,Gary W Beecham,Duane Beekly,David A Bennett,Eileen H Bigio,Thomas D Bird,Deborah Blacker,Bradley F Boeve,James D Bowen,Adam Boxer,James R Burke,Jacqueline Buros,Joseph D Buxbaum,Nigel J Cairns,Laura B Cantwell,Chuanhai Cao,Chris S Carlson,Regina M Carney,Steven L Carroll,Helena C Chui,David G Clark,Jason Corneveaux,Carl W Cotman,Paul K Crane,Carlos Cruchaga,Jeffrey L Cummings,Philip L De Jager,Charles DeCarli,Steven T DeKosky,F Yesim Demirci,Ramon Diaz-Arrastia,Malcolm Dick,Beth A Dombroski,Ranjan Duara,William D Ellis,Denis Evans,Kelley M Faber,Kenneth B Fallon,Martin R Farlow,Steven Ferris,Tatiana M Foroud,Matthew Frosch,Douglas R Galasko,Paul J Gallins,Mary Ganguli,Marla Gearing,Daniel H Geschwind,Bernardino Ghetti,John R Gilbert,Sid Gilman,Bruno Giordani,Jonathan D Glass,Alison M Goate,Robert C Green,John H Growdon,Hakon Hakonarson,Ronald L Hamilton,John Hardy,Lindy E Harrell,Elizabeth Head,Lawrence S Honig,Matthew J Huentelman,Christine M Hulette,Bradley T Hyman,Gail P Jarvik,Gregory A Jicha,Lee-Way Jin,Gyungah Jun,M Ilyas Kamboh,Jason Karlawish,Anna Karydas,John S K Kauwe,Jeffrey A Kaye,Nancy Kennedy,Ronald Kim,Edward H Koo,Neil W Kowall,Patricia Kramer,Walter A Kukull,James J Lah,Eric B Larson,Allan I Levey,Andrew P Lieberman,Oscar L Lopez,Kathryn L Lunetta,Wendy J Mack,Daniel C Marson,Eden R Martin,Frank Martiniuk,Deborah C Mash,Eliezer Masliah,Wayne C McCormick,Susan M McCurry,Andrew N McDavid,Ann C McKee,Marsel Mesulam,Bruce L Miller,Carol A Miller,Joshua W Miller,Thomas J Montine,John C Morris,Amanda J Myers,Adam C Naj,Petra Nowotny,Joseph E Parisi,Daniel P Perl,Elaine Peskind,Wayne W Poon,Huntington Potter,Joseph F Quinn,Ashok Raj,Ruchita A Rajbhandary,Murray Raskind,Eric M Reiman,Barry Reisberg,Christiane Reitz,John M Ringman,Erik D Roberson,Ekaterina Rogaeva,Roger N Rosenberg,Mary Sano,Andrew J Saykin,Julie A Schneider,Lon S Schneider,William Seeley,Michael L Shelanski,Michael A Slifer,Charles D Smith,Joshua A Sonnen,Salvatore Spina,Peter St George-Hyslop,Robert A Stern,Rudolph E Tanzi,John Q Trojanowski,Juan C Troncoso,Debby W Tsuang,Vivianna M Van Deerlin,Badri Narayan Vardarajan,Harry V Vinters,Jean Paul Vonsattel,Li-San Wang,Sandra Weintraub,Kathleen A Welsh-Bohmer,Jennifer Williamson,Randall L Woltjer

DOI: https://doi.org/10.1212/WNL.0b013e3182605801

IF: 9.9

2012-07-17

Neurology

Abstract:Objective: Recent genome-wide association studies (GWAS) of late-onset Alzheimer disease (LOAD) identified 9 novel risk loci. Discovery of functional variants within genes at these loci is required to confirm their role in Alzheimer disease (AD). Single nucleotide polymorphisms that influence gene expression (eSNPs) constitute an important class of functional variants. We therefore investigated the influence of the novel LOAD risk loci on human brain gene expression. Methods: We measured gene expression levels in the cerebellum and temporal cortex of autopsied AD subjects and those with other brain pathologies (∼400 total subjects). To determine whether any of the novel LOAD risk variants are eSNPs, we tested their cis-association with expression of 6 nearby LOAD candidate genes detectable in human brain (ABCA7, BIN1, CLU, MS4A4A, MS4A6A, PICALM) and an additional 13 genes ±100 kb of these SNPs. To identify additional eSNPs that influence brain gene expression levels of the novel candidate LOAD genes, we identified SNPs ±100 kb of their location and tested for cis-associations. Results: CLU rs11136000 (p = 7.81 × 10(-4)) and MS4A4A rs2304933/rs2304935 (p = 1.48 × 10(-4)-1.86 × 10(-4)) significantly influence temporal cortex expression levels of these genes. The LOAD-protective CLU and risky MS4A4A locus alleles associate with higher brain levels of these genes. There are other cis-variants that significantly influence brain expression of CLU and ABCA7 (p = 4.01 × 10(-5)-9.09 × 10(-9)), some of which also associate with AD risk (p = 2.64 × 10(-2)-6.25 × 10(-5)). Conclusions: CLU and MS4A4A eSNPs may at least partly explain the LOAD risk association at these loci. CLU and ABCA7 may harbor additional strong eSNPs. These results have implications in the search for functional variants at the novel LOAD risk loci.
Identification of novel risk genes for Alzheimer's disease by integrating genetics from hippocampus

Jie Li,Lingfang Li,Shanshan Cai,Kun Song,Shenghui Hu

DOI: https://doi.org/10.1038/s41598-024-78181-0

IF: 4.6

2024-11-13

Scientific Reports

Abstract:Alzheimer's disease (AD) stands as the most prevalent neurodegenerative ailment, presently lacking a definitive cure. Given that primary medications for AD patients in the early or middle stages demonstrate optimal efficacy, it becomes crucial to delve into the identification of risk genes associated with early onset. In our study, we compiled and integrated three transcriptomics datasets (GSE48350, GSE36980, GSE5281) originating from the hippocampus of 37 AD patients and 66 healthy controls (CTR) for comprehensive bioinformatics analysis. Comparative analysis with CTR revealed 25 up-regulated genes and 291 down-regulated genes in AD. Those down-regulated genes were notably enriched in processes related to the transmission and transport of synaptic signals. Intriguingly, 27 differentially expressed genes implicated in AD were also correlated with the Braak stage, establishing a connection with various immune cell types that exhibit differences in AD, including cytotoxic T cells, neutrophils, CD4 T cells, Th1, Th2, and Tfh. Significantly, a Cox model, constructed using nine feature genes, effectively stratified AD samples (HR = 2.72, 95% CI 1.94 ~ 3.81, P = 3.6e–10), highlighting their promising potential for risk assessment. In conclusion, our investigation sheds light on novel genes intricately linked to the onset and progression of AD, offering potential biomarkers for the early detection of this debilitating condition. This study contributes valuable insights toward enhancing the strategies for preventing and treating AD.

multidisciplinary sciences
Systems genetic dissection of Alzheimer's disease brain gene expression networks

Pinghan Zhao,Omar El Fadel,Anh Le,Carl Grant Mangleburg,Justin Dhindsa,Timothy Wu,Jinghan Zhao,Meichen Huang,Bismark Amoh,Aditi Sai Marella,Yarong Li,Nicholas T Seyfried,Allan I Levey,Zhandong Liu,Ismael Al Ramahi,Juan Botas,Joshua M Shulman

DOI: https://doi.org/10.1101/2024.10.04.616661

2024-10-04

Abstract:In Alzheimer's disease (AD), changes in the brain transcriptome are hypothesized to mediate the impact of neuropathology on cognition. Gene expression profiling from postmortem brain tissue is a promising approach to identify causal pathways; however, there are challenges to definitively resolve the upstream pathologic triggers along with the downstream consequences for AD clinical manifestations. We have functionally dissected 30 AD-associated gene coexpression modules using a cross-species strategy in fruit fly (Drosophila melanogaster) models. Integrating longitudinal RNA-sequencing and behavioral phenotyping, we interrogated the unique and shared transcriptional responses to amyloid beta (Aβ) plaques, tau neurofibrillary tangles, and/or aging, along with potential links to progressive neuronal dysfunction. Our results highlight hundreds of conserved, differentially expressed genes mapping to human AD regulatory networks. To confirm causal modules and pinpoint AD network drivers, we performed systematic in vivo genetic manipulations of 357 conserved, prioritized targets, identifying 141 modifiers of Aβ- and/or tau-induced neurodegeneration. We discover an up-regulated network that is significantly enriched for both AD risk variants and markers of immunity / inflammation, and which promotes Aβ and tau-mediated neurodegeneration based on fly genetic manipulations in neurons. By contrast, a synaptic regulatory network is strongly downregulated in human brains with AD and is enriched for loss-of-function suppressors of Aβ/tau in Drosophila. Additional experiments suggest that this human brain transcriptional module may respond to and modulate Aβ-induced glutamatergic hyperactivation injury. In sum, our cross-species, systems genetic approach establishes a putative causal chain linking AD pathology, large-scale gene expression perturbations, and ultimately, neurodegeneration.

Systems Biology
Identification of Immune Cells and Key Genes associated with Alzheimer's Disease

Chenming Liu,Xi Zhang,Huazhen Chai,Sutong Xu,Qiulu Liu,Yuping Luo,Siguang Li

DOI: https://doi.org/10.7150/ijms.66422

2022-01-01

Abstract:Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by cognitive impairment and memory loss, for which there is no effective cure to date. In the past several years, numerous studies have shown that increased inflammation in AD is a major cause of cognitive impairment. This study aimed to reveal 22 kinds of peripheral immune cell types and key genes associated with AD. The prefrontal cortex transcriptomic data from Gene Expression Omnibus (GEO) database were collected, and CIBERSORT was used to assess the composition of 22 kinds of immune cells in all samples. Weighted gene co-expression network analysis (WGCNA) was used to construct gene co-expression networks and identified candidate module genes associated with AD. The least absolute shrinkage and selection operator (LASSO) and random forest (RF) models were constructed to analyze candidate module genes, which were selected from the result of WGCNA. The results showed that the immune infiltration in the prefrontal cortex of AD patients was different from healthy samples. Of all 22 kinds of immune cells, M1 macrophages were the most relevant cell type to AD. We revealed 10 key genes associated with AD and M1 macrophages by LASSO and RF analysis, including ARMCX5, EDN3, GPR174, MRPL23, RAET1E, ROD1, TRAF1, WNT7B, OR4K2 and ZNF543. We verified these 10 genes by logistic regression and k-fold cross-validation. We also validated the key genes in an independent dataset, and found GPR174, TRAF1, ROD1, RAET1E, OR4K2, MRPL23, ARMCX5 and EDN3 were significantly different between the AD and healthy controls. Moreover, in the 5XFAD transgenic mice, the differential expression trends of Wnt7b, Gpr174, Ptbp3, Mrpl23, Armcx5 and Raet1e are consistent with them in independent dataset. Our results provided potential therapeutic targets for AD patients.
Theory of single bunch stability and dynamics in linacs with strong wakefields and misalignments

G. Guignard,J. Hagel

DOI: https://doi.org/10.1016/S0168-9002(99)00560-4

1999-09-21

Abstract:
APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer's Disease pathology

Augustine Chemparathy,Yann Le Guen,Sunny Chen,Eun-Gyung Lee,Lesley Leong,John Gorzynski,Guangxue Xu,Michael Belloy,Nandita Kasireddy,Andrés Peña Tauber,Kennedy Williams,Ilaria Stewart,Thomas Wingo,James Lah,Suman Jayadev,Chad Hales,Elaine Peskind,Daniel D Child,C Dirk Keene,Le Cong,Euan Ashley,Chang-En Yu,Michael D Greicius

DOI: https://doi.org/10.1101/2023.07.20.23292771

2023-07-24

MedRxiv

Abstract:The ε4 allele of apolipoprotein E (APOE) is the strongest genetic risk factor for sporadic Alzheimer's Disease (AD). Knockdown of this allele may provide a therapeutic strategy for AD, but the effect of APOE loss-of-function (LoF) on AD pathogenesis is unknown. We searched for APOE LoF variants in a large cohort of older controls and patients with AD and identified six heterozygote carriers of APOE LoF variants. Five carriers were controls (ages 71-90) and one was an AD case with an unremarkable age-at-onset between 75-79. Two APOE ε3/ε4 controls (Subjects 1 and 2) carried a stop-gain affecting the ε4 allele. Subject 1 was cognitively normal at 90+ and had no neuritic plaques at autopsy. Subject 2 was cognitively healthy within the age range 75-79 and underwent lumbar puncture at between ages 75-79 with normal levels of amyloid. The results provide the strongest human genetics evidence yet available suggesting that ε4 drives AD risk through a gain of abnormal function and support knockdown of APOE ε4 or its protein product as a viable therapeutic option.
Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease

Rebecca Panitch,Junming Hu,Weiming Xia,David A. Bennett,Thor D. Stein,Lindsay A. Farrer,Gyungah R. Jun

DOI: https://doi.org/10.1186/s13195-022-00975-z

2022-02-09

Alzheimer's Research and Therapy

Abstract:Abstract Background While Alzheimer disease (AD) is generally considered as a brain disorder, blood biomarkers may be useful for the diagnosis and prediction of AD brain pathology. The APOE ε4 allele has shown cerebrovascular effects including acceleration of blood-brain barrier (BBB) breakdown. Methods We evaluated the differential expression of previously established AD genes in brains from 344 pathologically confirmed AD cases and 232 controls and in blood from 112 pathologically confirmed AD cases and 67 controls from the Religious Orders Study and Memory and Aging Project. Differential gene expression between AD cases and controls was analyzed in the blood and brain jointly using a multivariate approach in the total sample and within APOE genotype groups. Gene set enrichment analysis was performed within APOE genotype groups using the results from the combined blood and brain analyses to identify biologically important pathways. Gene co-expression networks in brain and blood samples were investigated using weighted correlation network analysis. Top-ranked genes from networks and pathways were further evaluated with vascular injury traits. Results We observed differentially expressed genes with P < 0.05 in both brain and blood for established AD genes INPP5D (upregulated) and HLA-DQA1 (downregulated). PIGHP1 and FRAS1 were differentially expressed at the transcriptome-wide level ( P < 3.3 × 10 −6 ) within ε2/ε3 and ε3/ε4 groups, respectively. Gene set enrichment analysis revealed 21 significant pathways (false discovery rate P < 0.05) in at least one APOE genotype group. Ten pathways were significantly enriched in the ε3/ε4 group, and six of these were unique to these subjects. Four pathways (allograft rejection, interferon gamma response, peroxisome, and TNFA signaling via NFKB) were enriched for AD upregulated genes in the ε3/ε4 group and AD downregulated genes in subjects lacking ε4. We identified a co-expressed gene network in the brain that reproduced in blood and showed higher average expression in ε4 carriers. Twenty-three genes from pathway and network analyses were significantly associated with at least one vascular injury trait. Conclusion These results suggest that the APOE genotype contributes to unique expression network profiles in both blood and brain. Several genes in these networks are associated with measures of vascular injury and potentially contribute to ε4’s effect on the BBB.
Genome-wide analysis identifies a novel LINC-PINT splice variant associated with vascular amyloid pathology in Alzheimer’s disease

Joseph S. Reddy,Mariet Allen,Charlotte C. G. Ho,Stephanie R. Oatman,Özkan İş,Zachary S. Quicksall,Xue Wang,Jiangli Jin,Tulsi A. Patel,Troy P. Carnwath,Thuy T. Nguyen,Kimberly G. Malphrus,Sarah J. Lincoln,Minerva M. Carrasquillo,Julia E. Crook,Takahisa Kanekiyo,Melissa E. Murray,Guojun Bu,Dennis W. Dickson,Nilüfer Ertekin-Taner

DOI: https://doi.org/10.1186/s40478-021-01199-2

2021-05-21

Acta Neuropathologica Communications

Abstract:Abstract Cerebral amyloid angiopathy (CAA) contributes to accelerated cognitive decline in Alzheimer’s disease (AD) dementia and is a common finding at autopsy. The APOE ε4 allele and male sex have previously been reported to associate with increased CAA in AD. To inform biomarker and therapeutic target discovery, we aimed to identify additional genetic risk factors and biological pathways involved in this vascular component of AD etiology. We present a genome-wide association study of CAA pathology in AD cases and report sex- and APOE -stratified assessment of this phenotype. Genome-wide genotypes were collected from 853 neuropathology-confirmed AD cases scored for CAA across five brain regions, and imputed to the Haplotype Reference Consortium panel. Key variables and genome-wide genotypes were tested for association with CAA in all individuals and in sex and APOE ε4 stratified subsets. Pathway enrichment was run for each of the genetic analyses. Implicated loci were further investigated for functional consequences using brain transcriptome data from 1,186 samples representing seven brain regions profiled as part of the AMP-AD consortium. We confirmed association of male sex, AD neuropathology and APOE ε4 with increased CAA, and identified a novel locus, LINC-PINT, associated with lower CAA amongst APO Eε4-negative individuals (rs10234094-C, beta = −3.70 [95% CI −0.49—−0.24]; p = 1.63E-08). Transcriptome profiling revealed higher LINC-PINT expression levels in AD cases, and association of rs10234094-C with altered LINC-PINT splicing. Pathway analysis indicates variation in genes involved in neuronal health and function are linked to CAA in AD patients. Further studies in additional and diverse cohorts are needed to assess broader translation of our findings.

neurosciences
Exploring the role of common regulatory variants in the etiology of late-onset Alzheimer’s disease

Hao Wang,Min Zhu,Jian Wang,Yue Sun,Yu Tao,Qin He,Xiang Xu,Li Chen,David Saffen

DOI: https://doi.org/10.1186/1750-1326-7-S1-S22

2012-01-01

Molecular Neurodegeneration

Abstract:Background Late-onset Alzheimer’s disease (LOAD) is a complex disorder with a significant genetic component (heritability ~ 0.8). It is distressingly common: in the United States, approximately 13% of individuals over the age of 65 and 43% of individuals over the age of 85 are estimated to have AD [2011 Alzheimer’s Disease Facts and Figures, Alzheimer’s Association]. Although specific mutations have been linked to familial forms of AD, mutations in AD candidate genes among LOAD cases are rare. For this reason there is currently great interest in identifying common genetic variants that contribute to this disorder. The goal of the current study is to quantify allele-specific differences in the expression of mRNAs encoding candidate LOAD susceptibility genes in human brain and elucidate the genetic basis for this differential expression. Haplotypes or combinations of genotypes that correlate with mRNA should be useful as markers in future genetic association studies aimed at identifying genes that contribute to AD risk and protection.
Allele-specific analysis reveals exon- and cell-type-specific regulatory effects of Alzheimer’s disease-associated genetic variants

Liang He,Yury Loika,Alexander M. Kulminski

DOI: https://doi.org/10.1038/s41398-022-01913-1

2022-04-18

Translational Psychiatry

Abstract:Abstract Elucidating regulatory effects of Alzheimer’s disease (AD)-associated genetic variants is critical for unraveling their causal pathways and understanding the pathology. However, their cell-type-specific regulatory mechanisms in the brain remain largely unclear. Here, we conducted an analysis of allele-specific expression quantitative trait loci (aseQTLs) for 33 AD-associated variants in four brain regions and seven cell types using ~3000 bulk RNA-seq samples and >0.25 million single nuclei. We first develop a flexible hierarchical Poisson mixed model (HPMM) and demonstrate its superior statistical power to a beta-binomial model achieved by unifying samples in both allelic and genotype-level expression data. Using the HPMM, we identified 24 (~73%) aseQTLs in at least one brain region, including three new eQTLs associated with CA12 , CHRNE , and CASS4 . Notably, the APOE ε4 variant reduces APOE expression across all regions, even in AD-unaffected controls. Our results reveal region-dependent and exon-specific effects of multiple aseQTLs, such as rs2093760 with CR1 , rs7982 with CLU , and rs3865444 with CD33 . In an attempt to pinpoint the cell types responsible for the observed tissue-level aseQTLs using the snRNA-seq data, we detected many aseQTLs in microglia or monocytes associated with immune-related genes, including HLA-DQB1 , HLA-DQA2 , CD33 , FCER1G , MS4A6A , SPI1 , and BIN1 , highlighting the regulatory role of AD-associated variants in the immune response. These findings provide further insights into potential causal pathways and cell types mediating the effects of the AD-associated variants.

psychiatry
Identification of Genetic Risk Factors in the Chinese Population Implicates a Role of Immune System in Alzheimer's Disease Pathogenesis

Xiaopu Zhou,Yu Chen,Kin Y. Mok,Qianhua Zhao,Keliang Chen,Yuewen Chen,John Hardy,Yun Li,Amy K. Y. Fu,Qihao Guo,Nancy Y. Ip

DOI: https://doi.org/10.1073/pnas.1715554115

2018-01-01

Abstract:Alzheimer’s disease (AD) is a leading cause of mortality among the elderly. We performed a whole-genome sequencing study of AD in the Chinese population. In addition to the variants identified in or around the APOE locus (sentinel variant rs73052335, P = 1.44 × 10 −14 ), two common variants, GCH1 (rs72713460, P = 4.36 × 10 −5 ) and KCNJ15 (rs928771, P = 3.60 × 10 −6 ), were identified and further verified for their possible risk effects for AD in three small non-Asian AD cohorts. Genotype–phenotype analysis showed that KCNJ15 variant rs928771 affects the onset age of AD, with earlier disease onset in minor allele carriers. In addition, altered expression level of the KCNJ15 transcript can be observed in the blood of AD subjects. Moreover, the risk variants of GCH1 and KCNJ15 are associated with changes in their transcript levels in specific tissues, as well as changes of plasma biomarkers levels in AD subjects. Importantly, network analysis of hippocampus and blood transcriptome datasets suggests that the risk variants in the APOE , GCH1 , and KCNJ15 loci might exert their functions through their regulatory effects on immune-related pathways. Taking these data together, we identified common variants of GCH1 and KCNJ15 in the Chinese population that contribute to AD risk. These variants may exert their functional effects through the immune system.
Whole Exome Sequencing Analyses Identified Novel Genes for Alzheimer's Disease and Related Dementia

Ya-Ru Zhang,Bang-Sheng Wu,Shi-Dong Chen,Liu Yang,Yue-Ting Deng,Yu Guo,Xin-Rui Wu,Wei-Shi Liu,Ju-Jiao Kang,Feng,Wei Cheng,Jin-Tai Yu

DOI: https://doi.org/10.1002/alz.14181

2024-01-01

Alzheimer s & Dementia

Abstract:INTRODUCTION: The heritability of Alzheimer's disease (AD) is estimated to be 58%-79%. However, known genes can only partially explain the heritability. METHODS: Here, we conducted gene-based exome-wide association study (ExWAS) of rare variants and single-variant ExWAS of common variants, utilizing data of 54,569 clinically diagnosed/proxy AD and related dementia (ADRD) and 295,421 controls from the UK Biobank. RESULTS: Gene-based ExWAS identified 11 genes predicting a higher ADRD risk, including five novel ones, namely FRMD8, DDX1, DNMT3L, MORC1, and TGM2, along with six previously reported ones, SORL1, GRN, PSEN1, ABCA7, GBA, and ADAM10. Single-variant ExWAS identified two ADRD-associated novel genes, SLCO1C1 and NDNF. The identified genes were predominantly enriched in amyloid-beta process pathways, microglia, and brain regions like hippocampus. The druggability evidence suggests that DDX1, DNMT3L, TGM2, SLCO1C1, and NDNF could be effective drug targets. DISCUSSION: Our study contributes to the current body of evidence on the genetic etiology of ADRD. Highlights Gene-based analyses of rare variants identified five novel genes for Alzheimer's disease and related dementia (ADRD), including FRMD8, DDX1, DNMT3L, MORC1, and TGM2. Single-variant analyses of common variants identified two novel genes for ADRD, including SLCO1C1 and NDNF. The identified genes were predominantly enriched in amyloid-beta process pathways, microglia, and brain regions like hippocampus. DDX1, DNMT3L, TGM2, SLCO1C1, and NDNF could be effective drug targets.
Functional characterization of Alzheimer's disease genetic variants in microglia

Xiaoyu Yang,Jia Wen,Han Yang,Ian R. Jones,Xiaodong Zhu,Weifang Liu,Bingkun Li,Claire D. Clelland,Wenjie Luo,Man Ying Wong,Xingjie Ren,Xiekui Cui,Michael Song,Hongjiang Liu,Cady Chen,Nicolas Eng,Mirunalini Ravichandran,Yang Sun,David Lee,Eric Van Buren,Min-Zhi Jiang,Candace S. Y. Chan,Chun Jimmie Ye,Rushika M. Perera,Li Gan,Yun Li,Yin Shen

DOI: https://doi.org/10.1038/s41588-023-01506-8

IF: 30.8

2023-09-22

Nature Genetics

Abstract:Candidate cis -regulatory elements (cCREs) in microglia demonstrate the most substantial enrichment for Alzheimer's disease (AD) heritability compared to other brain cell types. However, whether and how these genome-wide association studies (GWAS) variants contribute to AD remain elusive. Here we prioritize 308 previously unreported AD risk variants at 181 cCREs by integrating genetic information with microglia-specific 3D epigenome annotation. We further establish the link between functional variants and target genes by single-cell CRISPRi screening in microglia. In addition, we show that AD variants exhibit allelic imbalance on target gene expression. In particular, rs7922621 is the effective variant in controlling TSPAN14 expression among other nominated variants in the same cCRE and exerts multiple physiological effects including reduced cell surface ADAM10 and altered soluble TREM2 (sTREM2) shedding. Our work represents a systematic approach to prioritize and characterize AD-associated variants and provides a roadmap for advancing genetic association to experimentally validated cell-type-specific phenotypes and mechanisms.

genetics & heredity

Letter: Lithium-induced tremor.

The Genetic Risk Effects of APOE Ε4 and Novel Variants on Chinese Familial and Sporadic AD.

APOE Genotype-specific Methylation Patterns are Linked to Alzheimer Disease Pathology and Estrogen Response

Redefining transcriptional regulation of the APOE gene and its association with Alzheimer’s disease

Non-coding Variability at the APOE Locus Contributes to the Alzheimer’s Risk

Multiomics integrative analysis identifies APOE allele-specific blood biomarkers associated to Alzheimer’s disease etiopathogenesis

P4-402 Alzheimer's Disease Drug Discovery Targeted to the APP MRNA 5′ Untranslated Region, a Validated Target

In vivo validation of late‐onset Alzheimer's disease genetic risk factors

Novel late-onset Alzheimer disease loci variants associate with brain gene expression

Identification of novel risk genes for Alzheimer's disease by integrating genetics from hippocampus

Systems genetic dissection of Alzheimer's disease brain gene expression networks

Identification of Immune Cells and Key Genes associated with Alzheimer's Disease

Theory of single bunch stability and dynamics in linacs with strong wakefields and misalignments

APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer's Disease pathology

Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease

Genome-wide analysis identifies a novel LINC-PINT splice variant associated with vascular amyloid pathology in Alzheimer’s disease

Exploring the role of common regulatory variants in the etiology of late-onset Alzheimer’s disease

Allele-specific analysis reveals exon- and cell-type-specific regulatory effects of Alzheimer’s disease-associated genetic variants

Identification of Genetic Risk Factors in the Chinese Population Implicates a Role of Immune System in Alzheimer's Disease Pathogenesis

Whole Exome Sequencing Analyses Identified Novel Genes for Alzheimer's Disease and Related Dementia

Functional characterization of Alzheimer's disease genetic variants in microglia